FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

NCT03841110 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors
Lymphoma
Gastric Cancer
Colorectal Cancer
Head and Neck Cancer
Squamous Cell Carcinoma
EGFR Positive Solid Tumor
HER2-positive Breast Cancer
Hepatocellular Carcinoma
Small Cell Lung Cancer
Renal Cell Carcinoma
Pancreas Cancer
Melanoma
NSCLC
Urothelial Carcinoma
Cervical Cancer
Microsatellite Instability
Merkel Cell Carcinoma

Interventions

DRUG: FT500
DRUG: Nivolumab
DRUG: Pembrolizumab
DRUG: Atezolizumab
DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: IL-2

Sponsor

Fate Therapeutics